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Abstract
Almost all kidney cancers are associated to immune dysfunction. Among these, renal cell 
carcinoma (RCC) represents approximately 2% of malignancies that affect adults and for 
90–95% of all kidney cancers. Recent evidences have collaborated to elucidate the mecha-
nisms involved in the development of this disease. In this view, dysfunctional neutrophil 
migration, as well as T lymphocyte-DC (dendritic cell) cross talk, DC maturation, immune 
cell metabolism, and reactivity and abnormal expression of cytokines and chemokines and 
their receptors have been highlighted in RCC and stroma cells. A rational development 
of novel therapies to recover antitumor activity of immune system is closely related to 
the understanding of the complex interactions between immune system and tumor. Some 
insights have been reached and immunomodulatory molecules, such as interleukin-2  
(IL-2) and IFN-α, immune checkpoint inhibitors, and chemokines antagonists have shown 
clinical efficacy. In this chapter, we overview the essential role of innate and adaptive 
immune response in RCC and discuss drugs approved or in development for its treatment.
Keywords: renal cell carcinoma, cytokines, chemokines, natural immunity, adaptive 
immunity
1. Introduction
Basically, the kidney is assigned to the urine production function. Indeed, kidney function 
overcomes this definition, since it is critical for the regulation of the body’s electrolytes, 
body’s fluid balance, body’s acid-base balance, and depuration of body waste. Thereby, dis-
eases such as kidney cancer compromise the kidney’s ability to perform its functions and 
bring consequences to the whole organism.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
According to the cell type where the tumor starts, kidney cancers are classified as renal cell 
carcinoma (RCC) subdivided in papillary RCC, chromophobe RCC, rare types of RCC, and 
unclassified RCC. Also, there are transitional cell carcinoma, Wilms’ tumor, which almost 
always occur in children and renal sarcoma [1–4].
Regardless of the category, kidney tumors have been associated with immune dysfunction [1–3, 5]. 
RCCs are rich in immune infiltrates consisting of T cells, natural killer (NK), DCs, macrophages 
among others [6, 7]. Different functions are ascribed to the different subsets of leukocytes. 
While the function of some of these cells is still elusive, like neutrophils which are essential com-
ponents of the RCC microenvironment, others have well-defined roles in tumor progression. 
For example, tumor-associated macrophages (TAMs) are known for their immunosuppressive 
action, which is associated to the secretion of inhibitory cytokines, the generation of reactive 
oxygen species, regulatory T cells (Treg) development, and the induction of angiogenesis 
[6, 8, 9]. Likewise, myeloid-derived suppressor cells (MDSCs) have been reported preventing 
the formation and execution of an effective antitumor immune response by the inhibition of 
effector T-cell function and the induction of Tregs maturation [6, 7], besides the inhibition of DC 
maturation and DC-induced T-cell activation and antitumor cytotoxic T lymphocyte (CTL) [10].
The role of the immune system in RCC is not only observed at the cellular level but also 
through inflammatory mediators, that is, through the action of cytokines and chemokines 
which act in tumor and stroma cells [11–13]. These mediators in RCC and stroma cells lead to 
survival, proliferation, and migration and favor angiogenesis and metastasis [11–13]. Thereby, 
the modulation of immune system effectors has shown therapeutic potential. In fact, strate-
gies involving immune checkpoint inhibitors, immunotherapy, and antagonists of chemokine 
receptors have proven clinical efficacy [14, 15].
Herein, we summarize relevant information about the role of natural and adaptive immunity 
in the development of RCC. Additionally, we describe cytokine and chemokine intracellular 
signaling pathways and mention how all knowledge has been useful for identification and 
advancement of therapeutic approaches for RCC.
2. Natural and adaptive immunity in RCC
The tumor microenvironment is a complex structure composed by several mediators that 
are involved in the cell signaling. The activation profile of extracellular matrix, fibroblasts, 
immune cells, blood vessels, and endothelial cells is essential to the pathogenesis of cancer, as 
well as to define therapeutic approaches [16–18]. Resident nontumor cells or infiltrated cells at 
tumor sites may even suppress the development of RCC. However, tumor cells can avoid the 
immune response coordinating changes in these cells and stimulating the secretion of immu-
nosuppressive factors for tumorigenesis, pro-inflammatory cytokines including angiogenic 
factors, thus ensuring the supply of nutrients by newly formed, blood vessels, which further 
allow for tumor growth [19, 20].
In addition, the profile of soluble factors, such as cytokines and chemokines, present in the 
tumor microenvironment may undergo dual polarization allowing either tumor growth 
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(leading to progressive disease) or its suppression (leading to regressive disease). Immune 
cells could interact with tumor cells, especially through immunosuppression, via cell-cell con-
tact, or by the release of factors that maintain a supportive environment for tumor growth. 
Through some soluble mediators, such as tumor necrosis factor-alpha (TNFα), immune cells 
can stimulate other cells, such as fibroblasts, to produce proteolytic enzymes for extracellular 
matrix remodeling and collagen, facilitating the spread of metastases. It may also stimulate 
the involvement of endothelial cells, which become able to form new vessels [18, 21, 22]. On 
the other hand, TNFα, which is mainly produced by macrophages, has also an important role 
in the recruitment of other immune cells to the tumor site where they will be able to assemble 
a response against the tumor. Thus, the constant interference of mediators may favor/inhibit 
an adequate environment for tumor maintenance and growth [18, 21].
Indeed, tissue repair promoted by inflammation is self-limited, and the imbalance on this pro-
cess may be pathogenic, giving inflammatory cells either a beneficial and/or a detrimental role 
in the pathogenesis of various diseases, including chronic inflammation and neoplasia [23]. 
The TAMs have at least two well-described states of polarization, according to immunological 
competences. While M1 (classically activated) macrophages can inhibit tumor growth, M2 
(alternatively activated) macrophages stimulate tumor growth [24–26]. The M1 polarization is 
functionally characterized by the release of pro-inflammatory cytokines (interleukin [IL]-1β, 
IL-6, and TNFα) and reactive nitrogen/oxygen species (RNI/ROS) acting as microbicidal and 
tumoricidal [24]. In the tumor context, some authors suggest that macrophages in the initial 
phase of tumorigenesis can naturally inhibit tumor growth, eradicate tumor cells, and stimu-
late the immune response. In contrast, M2 macrophages may favor neoplasia by producing 
anti-inflammatory cytokines that suppress the cellular response, release vascular endothelial 
growth factors (VEGFs), responsible for angiogenesis, and release transforming growth fac-
tors (TGF-beta) [27].
The different subtypes of T lymphocytes are also recruited into the tumor microenvironment 
and interact with tumor cells, which may induce tumor cell death, becoming anergic or even 
suppressing the immune response against the tumor [28, 29]. T CD8+ lymphocytes, also known 
as cytotoxic T cells, play an important role in the adaptive immunity in response to tumor-
specific epitopes. Together with NK and Natural killer T (NKT) cells, T CD8+ cells induce tumor 
cell death by apoptosis through the secretion of cytotoxic factor, such as granzymes and perfo-
rins. Besides, when the TCD8 lymphocyte is activated, it secretes IFN-gamma and IL2, activat-
ing other TCD8 cells and M1 macrophages, skewing the inflammatory response toward a Th1 
profile. However, RCC and some types of tumor-infiltrating immune cells, such as MDSCs, 
present in the tumor microenvironment can suppress antitumor response T cell mediated by 
the expression of programmed death ligand-1 (PD-L1, also known as B7-H1 or CD274) [30, 31].
CD4 T lymphocyte is endowed with great plasticity, being able to differentiate into Th1, Th2, 
Th3, Th17, and Treg subtypes. Treg cells play a critical role in the control of the acute phase of the inflam-
matory response through immunosuppression. High levels of Treg in the tumor microenviron-
ment are considered as poor prognosis for tumors, for example, in renal and pancreatic tumor, 
due to the recruitment of other immunosuppressive cells and the stimulation of the angiogenic 
process [29, 32]. MDSCs are involved in chronic inflammation processes, which are recruited 
by tumor or Treg, increasing immunosuppression in the tumor microenvironment [33]. 
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A common feature of almost all solid tumors is hypoxia that could lead to the stability of 
the HIF-1α transcription factor (hypoxia-inducible factor-1α). HIF-1α can bind to a hypoxia-
responsive element in the PD-L1 promoter leading to PD-L1 expression, not only on tumor cells 
but also on MDSCs, macrophages, and DCs within the tumor microenvironment [34].
PD-L1 binds with PD-1 present on the cell surface of activated T cells leading to prolifera-
tion blockade, dysfunctional response, and T-cell death. CTLA-4 (CTL -associated antigen 
4), a receptor also present in T cells, is the best studied inhibitory molecule, well known for 
its capacity of blocking T cell-mediated immune responses [35, 36]. CTLA-4 competes with 
CD28 for CD80 or CD86 binding. When the CTLA-4/CD80 or CD86 interaction occurs, the cell 
becomes anergic and dies. The overexpression of CTLA-4 is involved in several neoplastic, 
inflammatory, and autoimmune diseases [37]. The inhibition of T response allows for RCC to 
avoid effectors of immunologic control and facilitates invasion and metastasis. Accordingly, 
PD-L1 overexpression is related to worse prognosis for metastatic RCC, and it is therefore an 
important target for drug discovery [38, 39]. New drugs based on monoclonal antibodies, such 
as anti-PD-1 and anti-CTLA-4, have been strongly explored in clinical trial and proven to be 
efficacious to combinatorial treatments [39]. Indeed, immunotherapy is a promising therapeu-
tic strategy for different types of cancers, but it is often not sufficient to control tumor growth 
[40]. Several therapeutic strategies based on innate, adaptive, humoral, or cytokine immune 
system responses have been studied in order to combat tumor cells in the host [41–45].
Studies using allogeneic DCs in metastatic Renal Cell Carcinoma (mRCC) and melanoma 
patients are widespread due to the ability of these cells to mediate the cell signaling between 
the innate and adaptive immune response. As professional antigen-presenting cells (APCs), 
these cells phagocytose tumor cell particles, process them, and further present their epitopes 
to further activate effector lymphocytes [46]. APCs play a crucial role in coordinating the 
immune response, where the imbalance between populations of macrophages, immature, and 
mature DCs significantly affects the immune response against solid tumors [47]. Both DCs and 
macrophages can be activated by some microbial stimulus or cytokines in an inflammatory 
environment. DCs and macrophages could differentiate from monocytes, according to the 
tissue environment, where cytokines such as IL4 and macrophage colony-stimulating factor 
granulocytes (GM-CSF) may induce differentiation, followed by TNFα-induced maturation 
[47]. In the tumor context, the inflammatory profile present at different stages of disease devel-
opment may contribute to or eradicate the pathogenesis [47]. The International Society for the 
Biological Therapy of Cancer (iSBTc), together with the Society for Cancer Immunotherapy 
(SITC), has been discussing the theme with the purpose of advancing the critical understand-
ing of the involvement of inflammation during pathogenesis and cancer treatment [48, 49]. In 
fact, the dynamics of tumor progression along with immunoedition has been studied for years, 
through the realization of which cells, molecules, and pathways of the immune system are 
engaged at different steps of the evolution of cancers. Nonetheless, an integrative picture of the 
whole process is still missing [50, 51]. Vesely et al. described several interactions between innate 
and adaptive immunity in cancer, suggesting a dynamic immuno-delivery model, where cells 
such as M2 macrophages, MDSC, Th17, Treg, and TCD8+ overexpressing CTLA-4 receptor are 
present in chronic inflammation and favor the processes related to tumor progression [52]. In 
contrast, NK, NKT, TCD8+, TCD4+, M1 macrophages, DCs, Tγδ cells and IL12 and IFN-gamma 
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cytokines are important for equilibrium and elimination phases of tumor control [52]. Several 
cytokines are involved in the differentiation process of immune cells. Interferon-gamma 
(INF-gamma) belongs to interferon family and is a natural glycoprotein that shows antiviral, 
antiproliferative, and immunomodulatory properties. INF-gamma plays a key role in the tumor 
microenvironment, where it aids in tumor eradication. This cytokine is able to recruit and 
induce the proliferation of T lymphocytes in the tumor microenvironment, to activate innate 
immunity cells, rendering them cytotoxic, besides polarizing the Th1 response from T CD4 
Figure 1. Dual role of natural and adaptive immunity in RCC. Innate immune cells (dendritic cells, macrophages, NK 
cells, neutrophils, and MDSCs) and adaptive immunity (B and T cells) in the tumor microenvironment may undergo 
dual polarization allowing either tumor growth (leading to progressive disease) or its suppression (leading to regressive 
disease). Dendritic cells are primed by tumor antigens, which are then presented to T and B cells for adaptive responses. 
On the other hand, dendritic cells can directly drive tumor angiogenesis through the release of pro-angiogenic cytokines 
such as TNFα and CXCL8. Similarly, neutrophils in the tumor microenvironment are able to release pro-angiogenic 
factors and chemokines that could contribute for cancer progression and metastasis. T CD8+ lymphocytes, also known 
as cytotoxic T cells, play an important role against tumor cells under response to tumor-specific epitopes. However, the 
PD-L1/PD-1 interaction on CD8+ T-cell surface induces cellular energy suppressing the effector response, leading CD8 
T cell to death. Failure of CD8+ T cells to kill tumor cells involves signals from multiple cells including MDSC, Treg, 
and TAMs. NK cells are characterized by a high cytolytic capacity against transformed cancer cells by the secretion of 
granzyme and perforin. Tumor cells and fibroblasts also produce survival/growth-promoting chemokines. Metastatic 
cancer cells are facilitated by the upregulation of particular chemokine receptors (such as CXCR4) by tumor cells, which 
enables them to migrate to secondary tissues where the ligands are expressed.
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lymphocytes [53, 54]. IL1-beta is one of the major cytokines involved in the pro-inflammatory 
response, which is synthesized by several immune cells, such as monocytes, macrophages, 
DCs, B lymphocytes, NK cells, among others. It has similar activities as described for TNFα, 
favoring tumor invasion and the angiogenic process, as well as favoring vascular perme-
ability and facilitating the recruitment of immune system cells to the tumor microenviron-
ment [55]. However, TNFα is the main mediator of the acute inflammatory response, being 
secreted primarily by macrophages and T cells. TNFα causes vascular endothelial cells to 
increase the expression of leukocyte integrins inducing chemotaxis. In addition, TNFα also 
acts on phagocytic cells, which characterizes an autocrine effect, since macrophages, apart 
from secreting TNFα, may respond to the stimulus itself, releasing IL1-beta [56, 57]. IL12 is 
secreted primarily by macrophages, DCs, monocytes, and neutrophils. It has action in the 
activation of cytotoxic NK cells and TCD8 lymphocytes, but its main function in the antitumor 
activity is involved in the activation and proliferation of T lymphocytes and NK cells, which 
induces the production of IFN-gamma. Moreover, IL12 and INF-gamma together are able to 
differentiate T-helper cells into Th1 cells [58, 59]. IL6 is synthesized by mononuclear phago-
cytes, such as macrophages and also by some activated T cells and by other cell types that are 
not part of the immune system in response to microorganisms or IL1-beta and TNFα stimuli 
[60]. IL10 is a cytokine known to be anti-inflammatory, synthesized in the form of monomers 
of 18–20 kDa, being functional in the form of homodimers. This cytokine can be produced by 
Th2 lymphocytes, monocytes, and epithelial cells. Its main action is to suppress the synthesis 
of several inflammatory cytokines such as IL1-beta, TNFα, IL-6, IL-8, and IL-12, as well as 
hematopoietic growth factors (GM-CSF, G-CFS) and macrophage colony-stimulating factor 
(M-CFS). In addition, IL-10 can inhibit the synthesis of nitric oxide, gelatinase, and collage-
nase, avoiding tissue injury [61]. Although its role in the tumor context remains unclear, IL-17 
is a pro-inflammatory cytokine secreted by Th17 lymphocytes, which regulates NFkB and 
MAPK activities. It is constantly involved in the acute phase of inflammatory diseases, such as 
autoimmune diseases, and it is associated with poor prognosis in patients with RCC [62, 63].
Taken all these studies together, the dual role of natural and adaptive immunity in RCC is 
evident (Figure 1).
3. Cytokines and chemokine intracellular signaling pathways
Physiologically, inflammation is a mechanism of tissue reaction for elimination, neutral-
ization, and destruction of the cause of aggression, as injurious stimuli such as microbial 
pathogens, irritants, or toxic cellular components [64]. Cells of the immune system including 
monocytes, macrophages, neutrophils, basophils, DCs, mast cells, T cells, and B cells play a 
role in this process [64]. These events are in turn controlled by a host of extracellular molecu-
lar regulators, including members of the cytokine and chemokine families that mediate both 
immune cell recruitment and complex intracellular signaling control mechanisms; as a result, 
cells assemble and disassemble a complex array of signaling pathways as they move from 
inactive to dedicated roles within the inflammatory response site. Disruption of these path-
ways triggers inflammatory disorders that could contribute for the development of some 
diseases as kidney cancer and other types of cancers [65].
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Key pro-inflammatory cytokines in kidney cancer include interleukin-1 beta (IL-1β), IL-6, and 
TNFα, all of which signal via the type I cytokine receptors that are structurally divergent from 
other cytokine receptor types [66, 67]. IL-1 signaling starts through its binding to its receptor 
composed of two subunits, interleukin 1 receptor type I (IL-1RI) and interleukin 1 recep-
tor accessory protein (IL1RAP) [68, 69]. Signaling proceeds with TIR adaptor and MyD88 by 
recruitment of IL-1R-associated kinases (IRAKs), which promote TNFR-associated factor 6 
(TRAF6) polyubiquitination via lysine 63 linkages. Subsequently, TRAF6 interacts with the 
TAK1/TAB1/TAB2 complex that allows NFκB nuclear translocation (p65/p50) resulting in pro-
inflammatory gene expression [69]. Also, TAK1/TAB1/TAB2 complex triggers the activation 
of the mitogen-activated protein kinases (MAPKs), c-JunN-terminal kinase (JNK), and p38, 
which induce the expression of pro-inflammatory genes. Similarly, TNFα binding to TNFR1 
results in NFκB nuclear translocation, MAPKs, JNK, and p38, but signaling is coordinated 
by complex I (TRADD/TRAF2/RIP) [67, 70]. Importantly, TNFα signaling following receptor 
internalization is thought to be pro-apoptotic, via the formation of complex II (TRADD/FADD/
Pro-Caspase-8) [67]. On the other hand, IL-6 binds to the FIII domains of the IL-6R chains, 
unleashing its signal via the gp130 proteins [71, 72]. Consequently, Janus kinases (JAKs) are 
recruited to the receptor, phosphorylating it and themselves, triggering STAT3 activation and 
transcription of pro-inflammatory genes and intracellular adhesion molecules [64].
Currently, it is not fully understood how the signaling triggered by these cytokines contributes 
to tumor progression, but high serum levels of these pro-inflammatory cytokines are associated 
with advanced disease [73]. Some evidence has arisen, as follows. It is well known that angio-
genesis is stimulated by inflammatory mediators in the tumor microenvironment, such as those 
expressed by TAMs [74]. Interestingly, TAMs isolated from RCC tumors express high levels of 
IL-1β, TNFa, and IL-6 [75]. In addition, mouse models have demonstrated that the inhibition of 
IL-1β signaling reduced tumor blood vessel formation [76] and IL-1β mediates metalloprotein-
ase-dependent RCC tumor cell invasion through the activation of cytosine-cytosine-adenosine-
adenosine-thymidine (CCAAT) enhancer binding protein b [67]. Regarding TNFα signaling, 
many studies associated it to chemokine overexpression in tumor and nontumor cells [77, 78]. 
Moreover, TNFα plays an important role in the progression of RCC by inducing epithelial to 
mesenchymal transition and CD44 expression, which may be involved in the resistance to the 
sunitinib treatment [66]. There is no direct correlation between IL-6R and RCC development; 
however, RCC cells express high levels of IL-6, and its signaling activity seems necessary for 
carcinogenesis, tumor progression, and tumor evasion of the immune system. STAT3 activa-
tion by IL-6 promotes tumorigenesis by preventing apoptosis while enhancing proliferation, 
angiogenesis, invasiveness, and immune evasion [79]. For example, activated STAT3 induces 
HIF-1α-mediated VEGF expression in human RCC cell [79].
Besides these pro-inflammatory cytokines, other mediators act as crucial players in 
RCC. Chemotactic cytokines or chemokines are responsible for the recruitment of cells from 
both the innate and adaptive immune systems to the site of injury or infection [64]. Chemokines 
induce integrin expression, such as the β2-integrin lymphocyte function-associated antigen 
(LFA-1), in target leukocytes, thus acting in the arrest of these cells and favoring diapede-
sis through the endothelium [71]. Despite this, primary chemotaxis action, chemokines, and 
their receptors are physiological relevant in many biological process, such as the initiation 
of adaptive immune responses, immune surveillance and the migration, proliferation, and 
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survival signals in multiple cell types [64]. Chemokine signals are transduced through bind-
ing to members of the seven-transmembrane, G-protein-coupled receptor (GPCR) superfam-
ily [80]. GPCRs exist as a heterotrimer containing three subunits: α, β, and γ. In its inactive 
form, the G protein is complexed in α, β, and γ, with guanosine diphosphate (GDP) fixed to 
the α subunit. Once stimulated by a receptor activated by its ligand, the α subunit exchanges 
its GDP for Guanosine-5’-triphosphate (GTP) [81]. This causes the dissociation of α which 
separate β and γ subunits by interacting with an effector protein or ion channel in order to 
stimulate or inhibit secondary intracellular messengers [81]. CXCR4 is well known for its 
role in the homing of progenitor cells into the bone marrow and, recently, associated with 
poor RCC prognosis, and it is mainly coupled to the Gαi subunit, which, after dissociation of 
the Gαβγ complex upon CXCR4 stimulation (Figure 2), is traditionally been regarded as the 
major signaling subunit, inhibits adenylyl cyclase activity, and triggers MAPK and phospha-
tidylinositol-3-kinase (PI3K) pathway activation [82]. The Gβγ subunits, in turn, lead to the 
activation of phospholipase C (PLC), causing the hydrolysis of the phospholipid membrane 
phosphatidylinositol 4,5-bisphosphate (PIP2) in inositol 1,4,5-trisphosphate (IP3) and 1,2-dia-
cylglycerol (DAG) [13, 82]. IP3 can bind to channels of the endoplasmic reticulum, inducing 
the mobilization of Ca2+ ions [83, 84]. This could also be considered a downstream effect of 
Gαi activity, since the inhibition of Gαi activity by its potent inhibitor pertussis toxin has been 
reported to lead to a decreased Ca2+ mobilization from intracellular stores [85]. CXCR4 can 
also act by interaction with other Gα subunits, that is, Gαq or Gα12, each of which has been 
associated with different intracellular signaling cascades [86]. Indeed, chemokine receptors 
also activate signaling pathways independent of G proteins, including p38MAPK and JAK/
Stat to regulate cellular processes such as migration and gene transcription [87, 88].
Regarding the signals triggered by pro-inflammatory mediators in RCC, CXCL12 chemokine 
and its receptors CXCR4 and CXCR7 have gained prominence, since this pathway, which is 
associated with chronic inflammation, is upregulated in RCC [65, 89, 90]. In RCC cells and 
in other tumor cells, these chemokines activate the PI3K/Akt pathway; consequently, many 
downstream elements of the Akt pathway are regulated, leading to tumor cell survival 
[13, 91, 92]. Frequently, NFκB nuclear translocation is observed following transcription of 
various apoptosis inhibitors and cell-cycle-promoting genes [93], but can be activated through 
other pathways, such as PKC [94]. Other downstream targets of Akt include procaspase-9 and 
the pro-apoptotic Bcl-2 family member, BAD (Bcl-2/Bcl-XL-antagonist, causing cell death), 
both of which are inhibited upon phosphorylation. Other consequence of Akt activation is 
the inhibition of members of the FKHR (forkhead in rhabdomyosarcoma) family of transcrip-
tion factors, which induce the transcription of numerous apoptotic genes [95, 96]. Besides, 
Akt signaling could induce p53 degradation and inhibition of GSK-3β (glycogen synthase 
kinase-3β), leading to stabilization of β-catenin, resulting in the downstream inhibition of 
negative regulators of cell cycle and the activation of cell-cycle-promoting genes [97]. mTOR 
(mammalian target of rapamycin) activation is also induced by Akt, which leads to p70S6K 
(p70 S6 kinase) activation and thus enhances protein translation of numerous cell-growth 
regulators [13]. Furthermore, intracellular events triggered by the activation of chemokines 
receptors lead to ERK1/2 signaling, following the inhibition of procaspase-9 and BAD 
[98, 99], the induction of transcription factors involved in cell-cycle regulation, and differen-
tiation, thereby promoting cell proliferation [100]. Other MAPKs, including JNK, have also 
been implicated in chemokine-induced proliferation signaling [101]. Also, HIF-1α may be 
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induced by chemokines signaling that contributes to VEGF expression, which is known to be 
the inducer of CXCR4 expression [101]. It is important to mention that not all of these path-
ways have been studied in detail in RCC cells, but there is strong evidence of their involve-
ment in the development of this disease. For example, Rac1 was not previously reported to 
be involved in RCC development, but some studies have shown its role in controlling tumor 
cell growth and chronic kidney disease [102]. In summary, CXCL12, CXCR4, and CXCR7 
release result in the activation of transcription factors involved in antiapoptotic mechanisms, 
cell-cycle regulation, and growth factor production, favoring tumor growth and metastasis.
Also, there are some particularities regarding CXCR7 role in RCC, which are independent of 
GPCRs. CXCR7 plays a role as a decoy for CXCL12, promoting some CXCL12α accumulation 
and triggering a differential signaling by CXCR4 [103, 104]. Besides, CXCR7 interacts and 
signals by β-arrestin in a ligand-dependent manner [83, 104].
Figure 2. Signaling induced by CXCR4 via G protein. CXCL12 binding causes the dissociation of α which separate β 
and γ subunits; as a result, βγ PLC is activated leading to calcium mobilization. PI3K/Akt activation by Gα triggers 
a transduction signal that contributes with cell survival, proliferation, and migration, which is associated with RCC 
disease. In contrast, the antagonist of CXCR4 blocks CXCR4 intracellular pathway.
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Obviously, here we emphasize intracellular events in tumor cells. However, while some pro-
cesses take place within the tumor cells, others would occur in the stroma: it is the synergism 
between these responses that contributes to the progression of the disease. RCC and other 
tumors interact with the surrounding tumor stroma through a variety of cytokines, chemo-
kines, and growth factors [84]. The tumor chemotactic environment recruits inflammatory 
cells including neutrophils, macrophages, and lymphocytes. Although initially these cells may 
have a protective antitumoral role, as displayed by neutrophils, which have a higher cytotoxic 
activity against poorly metastatic cells, secondarily neutrophils could contribute to cancer pro-
gression. Leukocytes can produce cytokines, growth factors, and MMPs that enhance growth, 
proliferation, and angiogenesis, as exemplified by the TAMs, which release growth and angio-
genic factors (e.g., VEGF) and basic fibroblast growth factor [105]. Thus, cellular communica-
tion by paracrine and autocrine chemokine/cytokine signaling contributes for the survival and 
growth of metastatic cells. In other words, stroma cells may support tumors at the same time 
as that tumor cells in turn modulate the microenvironment within which they reside.
4. Immunomodulatory molecules as new therapeutic targets for RCC
Among the standard drugs for metastatic RCC treatment, the most effective regimens 
include the combination of targeted therapy agents and antiangiogenic agents (tyrosine 
kinase inhibitors, such as sorafenib, sunitinib, pazopanib, and axitinib), or an antiangiogenic 
antibody routinely employed in combination with interferon alpha (bevacizumab) [106, 107], 
and antiproliferative agents (mTOR inhibitors, such as temsirolimus and everolimus) [106, 107]. 
Despite the effectiveness of these therapies, resistance to antiangiogenic therapy almost always 
occurs and are associated with high toxicity and, consequently, serious adverse events.
Considering all knowledge previously mentioned in this chapter, it is not surprising that 
agents altering the immune response in order to prevent tumor growth and metastases have 
gained space in this scenario [12, 14, 108]. Known as immunomodulators, these molecules have 
been studied for some time now [109]. Among the first representatives of this class are IL-2 and 
interferon-alpha (IFN-α). IL-2 is a naturally occurring cytokine, which have antitumor activity 
by the induction of proliferation of NK cells, lymphokine-activated killer cells (LAKs), and 
other cytotoxic cells [110, 111]. IFN-α is also a molecule that had its clinical effect for the treat-
ment of RCC demonstrated years ago [109, 112]. It is a pleiotropic cytokine with immunomod-
ulatory activities that is able to induce the differentiation of monocytes into highly activated 
DCs, which are particularly effective in recognizing complex antigens and inducing T- and 
B-cell immunity and thus participate in the generation of antitumor T-cell immunity [112]. 
However, cytokine immunotherapies work effectively only in a minority of RCC patients and 
currently are not considered for the standard treatment of RCC due to their high toxicity.
In this context, cytokines have been exploited. Combination therapy using an antihuman 
IL-6R antibody with interferon has been suggested as a novel therapeutic approach for the 
treatment of RCC. Besides, an IL-6R-neutralizing antibody, tocilizumab, in combination with 
sorafenib suppressed tumor growth and inhibits angiogenesis in vivo more efficiently than 
sorafenib alone [113, 114]. Similarly, infliximab, an anti-TNFα monoclonal antibody that pre-
vents TNFα binding to its receptors, TNFR1 (p55 receptor) and TNFR2 (p75 receptor) and 
causes cell death via complement-mediated lysis through interaction with membrane-bound 
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TNF, has been considered for RCC treatment [115]. However, treatments with anti-TNFα 
monoclonal antibody showed varying results in independent studies, probably due to reac-
tions given by this cytokine to different conditions, environmental and genetic factors and/
or other unknown or unexplained factors [116]. Besides anti-TNFα strategies, targeting IL-1β 
has also been reported as possible therapy for RCC [117].
Promising candidates for RCC treatment have also been designed to specifically target chemo-
kines and their receptors. One of the most widely studied compounds is AMD3100 which is 
thought to specifically block CXCR4 signaling [118] and that acts directly in RCC tumor [91] cells 
as well as local antitumor immune response, by impairing Tregs function [119], know to sup-
press a whole range of immune cells including B cells, NK cells, NKT cells, CD4+ or CD8+ T cells, 
monocytes, and DCs [119]. Also, many other chemokine antagonists have also shown potential 
for clinical application in cancer treatment and could be useful for RCC treatment in the future. 
For example, anti-CXCR7-12G8 and CCX77, CXCR7 inhibitors or CTCE-9908, which is a peptide 
analog of CXCL12 and an active inhibitor of the ligand, has shown promising results as well as 
tolerated drug that stabilized disease in early clinical trials for late-stage cancer patients [12, 120].
Recently, antibodies that inhibit T-cell coinhibitory receptors have emerged as therapeu-
tic promises not only in the treatment of RCC but also in other tumors by inhibiting T-cell 
regulatory activity and increasing the antitumor immune response [14, 121]. Nivolumab and 
pembrolizumab (anti-PD-1) [14, 122], avelumab, and durvalumab (anti-PD-L1) are in late-
stage clinical development for a number of indications [14, 123], besides the first in its class, 
ipilimumab (anti-CTLA-4), already approved for use in a number of indications [14, 124].
Finally, the close relationship between cancer and immune system has suggested that current 
drug therapies used to treat inflammatory diseases or particular types of cancers could function 
as inhibitors of chemokine signaling and could therefore be redirected toward the treatment 
of other cancers [12, 116]. This hypothesis needs to be tested by further preclinical and clinical 
investigation, which elucidates how these drugs would act at molecular and systemic levels.
5. Role of immune system in kidney cancer and the future
The role of immune system in kidney cancer is becoming more clear, whereas new findings 
that arise from clinical trials and identification of additional predictive biomarkers increase 
our understanding of the tumor microenvironment. Looking to the future based on the 
knowledge we have today, the perspective is a better understanding of immune system in 
tumor stroma as well as in various steps in cancer growth and metastasis.
Regarding RCC therapy, a promising option is the combination therapy based on targeted 
agents (inhibition of mTOR or VEGF pathways associated with immunotherapies) or immu-
notherapy + immunotherapy, which would overcome tumor resistance, as well as to restore 
functional immune system cancer surveillance and response. Currently, there are many 
clinical trials investigating combination therapy: nivolumab (anti-PD-1) + ipilimumab (anti-
CTLA-4) [125], pembrolizumab (anti-PD-1) + ipilimumab (anti-CTLA-4) [126], pidilizumab 
(anti-PD-1) + vaccine (DC/RCC fusion cell vaccine) [127], atezolizumab (anti-PD-L1) + bevaci-
zumab (anti-VEGF) [127], nivolumab (anti-PD-1) + bevacizumab (anti-VEGF) [128], pembroli-
zumab (anti-PD-1) + pazopanib (TKI) [129], nivolumab (anti-PD-1) + sunitinib [130].
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Also, cell-based therapies have become interesting, which includes adoptive T-cell therapies 
such as tumor-infiltrating lymphocytes (TILs), T-cell receptor (TCR), and chimeric antigen 
T-cell (CAR-T) therapy [127].
Other promising alternative of therapy for RCC is vaccine-based immunotherapy. AGS-003 is 
an autologous DC vaccine that is generated from host DCs in response to tumor mRNA [131], 
which is also to investigate in combination with sunitinib [132].
All these therapeutic investigations highlighted the importance of immune system in the 
future study about RCC. Information about immune system may be decisive for clinical 
decisions.
6. Conclusion
Immune system plays a role in kidney cancer, and this should be considered for both the 
understanding of the disease and the development of novel therapies.
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